公开(公告)号：WO2013147568A1

公开(公告)日：2013-10-03

申请号：PCT/KR2013/002699

申请日：2013-04-01

Applicant: KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY

Inventor： KIM, Dong Jin ,  YOO, Kyung Ho ,  KIM, Young Soo ,  PARK, Woong Seo ,  KANG, Yong Koo ,  KIM, Hye Yun ,  KIM, Yun Kyung ,  PARK, Ki Duk ,  KIM, Maeng Sup ,  SUH, Kwee Hyun ,  AHN, Young Gil

IPC: C07D413/12 ,  C07D307/86 ,  A61K31/421 ,  A61P25/00

CPC classification number: C07D413/12 ,  C07D307/81 ,  C07D405/12

Abstract: The present invention provides an aminostyrylbenzofuran compound of Formula (I), and a pharmaceutical composition comprising same. The pharmaceutical composition of the present invention comprising the compound of Formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate, and a solvate thereof as an active ingredient can be useful for the prevention and treatment of degenerative brain diseases caused by accumulation of beta-amyloid.

Abstract translation: 本发明提供式（I）的氨基苯乙烯基苯并呋喃化合物和包含其的药物组合物。 包含式（I）化合物，其药学上可接受的盐，异构体，水合物和溶剂合物作为活性成分的本发明的药物组合物可用于预防和治疗由积累引起的退行性脑病 的β-淀粉样蛋白。

公开(公告)号：EP3202759A1

公开(公告)日：2017-08-09

申请号：EP15847985.7

申请日：2015-09-24

Applicant: Korea Institute of Science and Technology

Inventor： PARK, Ki Duk ,  LEE, Changjoon Justin ,  KIM, Dong Jin ,  PAE, Ae Nim ,  CHOO, Hyun Ah ,  MIN, Sun Joon ,  KANG, Yong Koo ,  KIM, Yun Kyung ,  SONG, Hyo Jung ,  CHOI, Ji Won ,  NAM, Min Ho ,  HEO, Jun Young ,  YEON, Seul Ki ,  JANG, Bo Ko ,  JU, Eun Ji ,  JO, Seon Mi ,  PARK, Jong-Hyun

IPC: C07C237/20 ,  C07C237/04 ,  C07C231/12 ,  C07C309/04 ,  A61K31/16 ,  A61K31/167

Abstract: The present disclosure relates to an α-aminoamide derivative compound and a pharmaceutical composition containing the same. According to various embodiments of the present disclosure, provided is a therapeutic agent which can overcome the disadvantages of existing drugs used as a MAO-B inhibitor and, specifically, reversibly inhibits MAO-B through a non-covalent bond so as to alleviate or eliminate the side effects of the existing drugs which exhibit a therapeutic effect by irreversibly acting via a covalent bond with MAO-B. Particularly, a new compound having superior stability and efficacy compared to the existing reversible MAO-B inhibitors may be provided.

Abstract translation: 本公开涉及α-氨基酰胺衍生物化合物和含有其的药物组合物。 根据本公开的各种实施方式，提供了一种治疗剂，其可以克服现有药物用作MAO-B抑制剂的缺点，并且具体地通过非共价键可逆地抑制MAO-B，从而缓解或消除 现有药物通过与MAO-B通过共价键发挥不可逆作用而表现出治疗效果的副作用。 特别地，可以提供与现有可逆MAO-B抑制剂相比具有优良稳定性和功效的新化合物。

公开(公告)号：EP3838896A1

公开(公告)日：2021-06-23

申请号：EP19849176.3

申请日：2019-08-19

Applicant: Korea Institute of Science and Technology

Inventor： PARK, Ki Duk ,  PAE, Ae Nim ,  LIM, Sang Min ,  PARK, Jong Hyun ,  CHOI, Ji Won ,  KIM, Siwon ,  KIM, Hyeon Jeong ,  YEON, Seul Ki

IPC: C07D401/12 ,  A61K31/44 ,  A61K31/496 ,  A61K31/5355 ,  C07D413/12

Abstract: The present invention relates to a novel halo-(3-(phenylsulfonyl)prop-1-enyl)pyridine derivative or a pharmaceutically acceptable salt thereof; a preparation method thereof; and an Nrf2 activator and a pharmaceutical composition for preventing or treating diseases induced by a decrease in Nrf2 activity, both of which comprise the same as an active ingredient.

公开(公告)号：EP4245749A1

公开(公告)日：2023-09-20

申请号：EP21892368.8

申请日：2021-11-12

Applicant: Institute for Basic Science ,  Korea Institute of Science and Technology

Inventor： LEE, Chang Jun ,  CHUN, Heejung ,  WON, Woojin ,  PARK, Ki Duk ,  PARK, Jong Hyun ,  PAE, Ae Nim ,  CHOI, Ji Won ,  LEE, Elijah ,  PARK, Sun Jun ,  KIM, Hyeon Jeong ,  KIM, Yoowon ,  KIM, Byung Eun ,  KIM, Siwon

IPC: C07C211/53 ,  A61K31/136 ,  A61P25/28 ,  A23L33/10 ,  A23L29/00

Abstract: The present invention provides a novel aminoaromatic compound or a pharmaceutically acceptable salt thereof, a pharmaceutical composition that is for preventing or treating neurodegenerative diseases and comprises same as an active ingredient, and a health functional food composition for preventing or ameliorating neurodegenerative diseases.

公开(公告)号：EP4534528A1

公开(公告)日：2025-04-09

申请号：EP23816418.0

申请日：2023-06-05

Applicant: Korea Institute of Science and Technology

Inventor： PARK, Ki Duk ,  PARK, Jong-Hyun ,  CHOI, Ji Won ,  CHO, Sung Jin ,  KIM, Hyeon Jeong ,  PARK, Sun Jun ,  KIM, Yoowon ,  KIM, Byungeun ,  KIM, Jushin ,  LEE, Elijah Hwejin ,  KIM, Rium ,  KIM, Jaehwan

IPC: C07D213/24 ,  A61K31/44 ,  A61K31/505 ,  A61K31/444 ,  A61K31/5377 ,  A61P1/16 ,  A61P13/12 ,  A61P11/00 ,  A61P25/28 ,  A61P17/06

Abstract: The present invention relates to a sulfanone derivative or a pharmaceutically acceptable salt thereof, and a composition containing the derivative as an active ingredient for the prevention or treatment of cancer, and the sulfanone derivative of the present invention or a pharmaceutically acceptable salt thereof exhibits an excellent effect on Nrf2 activation and a high solubility and pharmaco-metabolic stability, has anti-inflammatory and antioxidant effects, and improves motor performance and cognitive ability, and thus can be used for the prevention or treatment of diseases induced by a decrease in the Nrf2 activity, preferably liver diseases, kidney diseases, lung diseases, neurodegenerative diseases, mitochondrial myopathy, Friedreich's ataxia, corneal endothelial cell loss, psoriasis, and the like.